• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHAO Jie,CHAI Fayong,SHI Yan,XING Xiaomin,FANG Juanjuan,CAO Hongyan.Comparative analysis and application of pharmaceutical manufacturing licensing systems in Australia and China[J].Journal Of Pharmaceutical Research,2026,45(9):1077-1080[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 227times   Download 198次 QR Code for this article
Scan with your phone!
澳大利亚与我国药品生产许可制度的对比分析与应用
赵杰,柴发永,石岩,邢小敏,房娟娟,曹鸿雁
Font:Larger+|Default|Smaller-
(山东省食品药品审评查验中心,山东 济南 250014)
摘要:
当前,国内医药产业正逐渐登上国际舞台,澳大利亚作为国际药品认证合作组织(PIC/S)成员国之一,通过澳大利亚治疗用品管理局(TGA)的药品生产质量管理规范(GMP)认证,意味着获得了包括欧盟50多个国家在内的PICS成员国的药品准入。本文简要介绍了TGA的组织机构,生产许可流程,对比了国内药品生产许可与澳大利亚TGA生产许可流程的逻辑差异以及我国药品生产企业申请海外GMP认证的痛点与解决之道,以期帮助国内药品生产企业进行自身产业布局,简化澳大利亚 GMP 认证程序,顺利进入国际市场。
关键词:  澳大利亚  组织机构  生产许可  对比分析
DOI:10.13506/j.cnki.jpr.2026.09.018
基金项目:
Received Date:March 05, 2026   Revision Date:May 29, 2026   Publication Date:September 30, 2026
Comparative analysis and application of pharmaceutical manufacturing licensing systems in Australia and China
ZHAO Jie,CHAI Fayong,SHI Yan,XING Xiaomin,FANG Juanjuan,CAO Hongyan
(Center for Evaluation and Certification,Shandong Food and Drug Administration,Jinan 250014,China)
Abstract:
At present, China's pharmaceutical industry is gradually gaining prominence on the international stage. As a member of PIC/S, obtaining GMP certification from Australia's TGA grants access to pharmaceutical markets in over 50 countries, including all PIC/S member states such as those in the EU. This article outlines the organizational structure of the Therapeutic Goods Administration (TGA) and its pharmaceutical manufacturing licensing procedures. It further compares the core logical differences between domestic pharmaceutical manufacturing licensing systems and Australia's TGA certification framework, identifies the pain points encountered by Chinese pharmaceutical enterprises during overseas Good Manufacturing Practice (GMP) certification applications, and proposes targeted solutions. The study aims to provide practical references for domestic pharmaceutical manufacturers to optimize their industrial layout, simplify the Australian GMP compliance process, and facilitate smooth access to the international pharmaceutical market.
Key words:  Australia  TGA structure  Manufacturing licence  Comparative analysis
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.